PT  - JOURNAL ARTICLE
AU  - Nichols, Emma Hitt
ED  - Hartung, Hans-Peter
TI  - CARE-MS II Follow-up: Improvements with Alemtuzumab Maintained for 4 Years
DP  - 2014 Jul 01
TA  - MD Conference Express
PG  - 10--11
VI  - 14
IP  - 29
4099  - http://mdc.sagepub.com/content/14/29/10.short
4100  - http://mdc.sagepub.com/content/14/29/10.full
AB  - Improvements in annualized relapse rate (ARR) and Expanded Disability Status Scale (EDSS) score were maintained throughout 4 years following treatment with alemtuzumab for 2 years in patients with relapsing-remitting multiple sclerosis (RRMS) who relapsed on prior therapy. This article presents data from the Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab trial [NCT00930553; Hartung H-P et al. ECTRIMS 2014 (poster P043)].